The team presents TCX-101 and is available for partnering meetings.
Tacalyx attends the AACR Annual Meeting 2024 in San Diego and presents new preclinical data on TCX-101.
"This event is a fantastic opportunity for us to showcase our latest advancements and explore partnerships to further elevate our cancer research."
— Prof. Dr. Matthias Ocker, Head of Experimental Medicine
Press releases
€11 million from the existing syndicate in a first closing of the seed extension. TCX-201 is selected as first clinical candidate, with a CTA filing planned for 2027.
Scientific presentations
Two posters at the AACR Annual Meeting 2026 in San Diego: the preclinical profile of first clinical candidate TCX-201 (Poster 5631) and TCX-101 as a trispecific T-cell engager (Poster 5584).
Company
Scientific Advisory Board meeting in Berlin, Clinical Advisory Board meeting and AACR Oncology Industry Partnering Event in San Diego, followed by two posters at AACR 2026.